Despite advances in the efficacy and specificity of cancer treatments over the last decade, pancreatic cancer remains one of the leading causes of death worldwide. The most common type of pancreatic tumor, Pancreatic Ductal Adenocarcinoma (PDAC), has distinctly poor patient outcomes due to its ...
COVID-19 is an emerging, rapidly evolving siituation.
What people with cancer should know: https://www.cancer.gov/coronavirus
Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers
Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
News and Announcements
August 5, 2021
Lung cancer remains the leading cause of cancer-associated death in the United States and worldwide. Patients with a subtype called lung adenocarcinoma (LUAD) have benefited from the development of new targeted medicines, but the search for effective new therapies for another subtype called lung ...
July 6, 2021
In the era of precision medicine, human epidermal growth factor receptor 2 (HER2) is one of the important predictive and prognostic biomarkers in breast cancer. At present, conventional HER2-targeting therapies improve outcomes for patients with HER2-positive breast cancer, defined as tumors having ...
June 30, 2021
Kidney cancer is the eighth most diagnosed cancer for both men and women in the United States, and about 76,000 new cases and nearly 14,000 deaths are expected in 2021. It is a category that includes many different kinds of cancer and is dominated by renal cell carcinoma.
June 24, 2021
Adult acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. It is characterized by an aberrant proliferation of immature myeloblasts that infiltrate the bone marrow and impair normal hematopoiesis. AML is the most common type of acute leukemia in adults and usually worsens quickly if ...
June 22, 2021
In the age of personalized cancer therapy, genetic sequencing technologies allow clinicians to rapidly pinpoint mutations likely involved in driving patient-specific tumorigenesis and disease progression. These oncogenic mutations lead to the aberrant activation of signaling pathways involved in ...
June 21, 2021
Advancements in science and health care are made possible through widespread access to results from cutting-edge research, enabling scientists to use and build on this knowledge. A critically important aspect of the success of the Human Genome Project was its approach to immediately release pre- ...
June 17, 2021
UniProt, the leading online protein reference library, has expanded its collaboration with the National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC). In addition to searching for a protein-of-interest in UniProt, which includes cross-reference links to the NCI CPTAC ...
June 7, 2021
In biomedical research, sample mislabeling or incorrect annotation has been a long-standing issue contributing to irreproducible results and invalid conclusions. These issues are particularly prevalent in large scale multi-omics studies, in which multiple different omics experiments are carried out ...
May 24, 2021
Protein/Peptide mass spectrometry (MS) is an enabling technology that is ideally suited for precision diagnostics, due to its quantitative measurements that can be multiplexed and its ability to directly identify proteoforms. As a result, interest on the widespread implementation of quantitative ...
April 1, 2021
Where is cancer research headed in the next decade? Scientists and oncologists at the National Cancer Institute share their thoughts on the NEXT HORIZON IN PRECISION ONCOLOGY - proteogenomics.
March 25, 2021
TGFβ is a cytokine with many, often paradoxical, roles in cancer biology. Acting as a tumor suppressor, TGFβ exerts negative control on epithelial cell proliferation - a function that tumor cells must overcome in order to progress to malignant disease. On the other hand, TGFβ also acts as a pro- ...
March 10, 2021
CPTAC researchers out of the University of Michigan have hit another home run. The Nesvizhskii lab, developer of the FragPipe proteomics pipeline, has developed an extension of its MSFragger flagship software to now identify N- and O-linked glycopeptides. The study was recently published in Nature ...
March 1, 2021
The National Cancer Institute (NCI) of the National Institutes of Health is pleased to announce the signing of two new memoranda of understanding (MOUs) for international cancer research and care, as well as new efforts in the emerging scientific area of proteogenomics for precision oncology. MOUs ...
February 22, 2021
Glioblastoma is among the most aggressive and devastating of cancers. While rare compared with other cancers, it’s the most common type of brain cancer. Even with intensive therapy, relatively few patients survive longer than two years after diagnosis, and fewer than 10% of patients survive beyond ...
January 26, 2021
Prostate cancer screening is typically done by evaluation of levels of prostate-specific antigens (PSA). Unfortunately, its effectiveness in stratifying low risk patients from those with aggressive (AG) prostate cancer is poor. Localized in the Golgi, α (1,6) fucosyltranferase (FUT8), a ...
January 7, 2021
Proteogenomic analysis may offer new insight into matching cancer patients with an effective therapy for their particular cancer. A new study identifies three molecular subtypes in head and neck squamous cell carcinoma (HNSCC) that could be used to better determine appropriate treatment.
December 15, 2020
Activating point mutations in ErbB/Her2 receptor tyrosine kinases have an infamous role in promoting oncogenesis across several different cancers, including breast and lung. Heterodimer activation of the ErbB2/ErbB3 oncogenic unit induces cancer cell proliferation via PI3K/AKT signaling pathways.
December 8, 2020
In case you missed it, this final article (part 2 of 2) in the Investigator Spotlight Series, developed and written by Dr. Dawn Hayward, Office Clinical Cancer Proteomic Research (OCCPR) NCI Communications Fellow, highlights our up and coming Clinical Proteomic Tumor Analysis Consortium (CPTAC) ...
December 1, 2020
A comprehensive “proteogenomic” analysis of the proteins, genes, and RNA transcription involved in pediatric brain tumors has yielded a more complete understanding of these tumors, which are the leading cause of cancer-related deaths in children. The results could help physicians more accurately ...